Sensei Biotherapeutics Inc. (SNSE) filed a registration statement with the U.S. Securities and Exchange Commission on April 28, 2026 to register 24.9 million shares for resale by existing shareholders. The filing is a secondary offering, allowing current owners to sell shares without the company issuing new equity.
The move follows a sharp decline in the company’s cash reserves, which fell from $41.3 million at the end of 2024 to $25.0 million as of September 30, 2025, and to $21.2 million at the end of 2025. The quarterly burn rate, driven by research and development and general‑administrative expenses, averaged $5.6 million per quarter in 2025, with the most recent quarter showing $4.6 million. The declining cash balance and high burn rate leave the company with a runway of roughly five quarters, prompting shareholders to seek liquidity.
The shares being registered for resale include Merger Conversion Shares, Private Placement Conversion Shares, and Warrant Conversion Shares, all of which were issued as part of the February 18, 2026 acquisition of Faeth Therapeutics and a concurrent $200 million private placement of Series B non‑voting convertible preferred stock. The Faeth acquisition added the PIKTOR program to Sensei’s pipeline but also contributed to the company’s cash outflows, as Faeth reported a 2025 net loss of $16.0 million and $20.4 million in cash and restricted cash.
Management has not issued new guidance following the filing, but the secondary offering signals that shareholders are looking to exit positions amid the company’s ongoing liquidity challenges. In a March 30, 2026 press release, President & General Counsel Christopher Gerry said the company was “entering 2026 with a clear path forward” after the acquisition, but the recent filing suggests that the capital infusion may be insufficient to sustain operations beyond the next few quarters.
The registration is expected to become effective shortly after the SEC’s review. If the shares are sold at market prices, the transaction could provide a short‑term infusion of capital for the company, but it could also dilute remaining equity holders. The filing underscores the need for Sensei to secure additional funding or to accelerate its clinical programs to improve cash flow.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.